Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933320 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL29313151 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL3633660 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL19880428 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL26211290 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL14536466 | 0.76 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL170842 | 0.75 | — | — | |
| SCHEMBL18629578 | 0.74 | ANPEP (0.38) | ALDH1A1CYP3A4TSHRANPEP | |
| SCHEMBL21983908 | 0.73 | KISS1R (0.36) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL172289 | 0.73 | TSHR (0.78) | ALDH1A1CYP3A4TSHRANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | ALDH1A1 3843/4885CYP3A4 2975/4885TSHR 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.